Deutsche Bank Aktiengesellschaft Reaffirms “Sell” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by equities research analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Wednesday,Digital Look reports. They presently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential downside of 2.88% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Citigroup boosted their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Jefferies Financial Group reiterated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research note on Monday, August 3rd. Finally, Berenberg Bank reissued a “buy” rating and set a £160 price objective on shares of AstraZeneca in a report on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of £152.17.

AstraZeneca Stock Up 0.3%

LON AZN opened at £118.41 on Wednesday. The business has a fifty day moving average price of £129.43 and a two-hundred day moving average price of £138.52. The stock has a market capitalization of £183.65 billion, a PE ratio of 17.73, a PEG ratio of 0.86 and a beta of 0.21. AstraZeneca has a fifty-two week low of £107.84 and a fifty-two week high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.